Medical experts and pharmaceutical companies gathered in Istanbul for the European Congress on Obesity 2026 to discuss a new generation of obesity treatments. The discussions focused on transitioning obesity care from simple weight reduction to managing a chronic disease, emphasizing overall health improvements and the introduction of oral pills and long-acting injections.
European Congress on Obesity 2026 in Istanbul
The European Congress on Obesity (EASO 2026), held in Istanbul and sponsored by MPC, has emerged as a central forum for global medical professionals to redefine the clinical approach to weight management. The event brought together doctors, researchers, and pharmaceutical representatives to present the latest protocols for treating obesity and therapeutic nutrition.
A primary theme of the congress is the shift in how the medical community perceives obesity. Experts at the event emphasized that obesity is no longer viewed as a problem related to appearance or lifestyle
, but is instead recognized as a chronic and complex disease
associated with dozens of health complications. This paradigm shift moves the goal of treatment beyond the scale, focusing instead on the improvement of general health and the overall quality of life for patients.
Among the participants discussing these shifts was Dr. Mohammed Al-Duwairi, a general practitioner and public health specialist, who joined other professionals in exploring the latest advancements in obesity studies during the Istanbul sessions.
New Delivery Methods for Obesity Medications
The congress highlighted a transition in the administration of obesity drugs, moving toward options that increase patient compliance and ease of use. Discussions focused on a new generation of treatments that include oral pills and long-acting injections, some of which are administered on a monthly basis.
These pharmaceutical advancements aim to move beyond the limitations of daily or weekly dosing. Researchers presented data on how these new delivery systems affect not only weight but also metabolic health. The discussions extended to the systemic impact of these drugs, with specific studies examining their influence on metabolism and the treatment of sleep disorders associated with obesity.
The clinical focus has also expanded to address demographic-specific needs. The congress included sessions on the impact of these new treatments on women’s health, recognizing that metabolic responses and health complications often differ by gender.
Long-term Cardiovascular Outcomes and Surgical Alternatives
While the pharmaceutical innovations discussed in Istanbul show promise, recent clinical data suggests that medication may not always be the most effective route for long-term risk reduction. A study released by Mayo Clinic on May 7, 2026, indicates a significant difference in outcomes between surgical and pharmacological interventions.
The Mayo Clinic research found that bariatric surgeries reduce the long-term risk of heart disease to a greater degree than weight-loss medications. This finding provides a critical counterpoint to the current trend of relying solely on the new generation of obesity drugs, suggesting that for certain patients, surgical intervention remains the superior option for cardiovascular protection.
This tension between pharmacological and surgical efficacy is a key point of debate for clinicians. The goal is to determine which patient profiles benefit most from the new monthly injections or oral pills and which require the more invasive but potentially more protective results of bariatric surgery.
Expanding the Clinical Scope of Obesity Care
The current medical trajectory, as evidenced by the EASO 2026 proceedings, is toward a multidisciplinary approach. Because obesity is treated as a chronic disease, the focus is shifting toward the management of comorbidities rather than just the reduction of body mass index (BMI).
The integration of sleep medicine and metabolic health into obesity protocols suggests that future treatments will likely be tailored to the specific complications a patient faces. By treating obesity as a systemic illness, clinicians aim to reduce the burden of associated chronic conditions, thereby improving the patient’s long-term prognosis and daily functioning.
As the pharmaceutical industry continues to develop long-acting and oral alternatives, the medical community remains focused on balancing these conveniences with the proven long-term cardiovascular benefits of surgery. The ongoing research presented in Istanbul suggests that the next phase of obesity care will be defined by precision medicine, where the choice between a pill, an injection, or a surgical procedure is dictated by the patient’s specific cardiovascular risk profile and metabolic needs.
Consult your healthcare provider for medical advice regarding obesity treatments and weight loss medications.